LeMaitre Vascular Inc LMAT

Healthcare Medical Devices

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Company’s principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.

NDAQ:LMAT - Post by User

LeMaitre Vascular Inc

<< Previous

Bullboard Posts

Next >>

Post by aett258on Jul 29, 2016 7:40am

144 Views

Post# 25094761

Record Q2 2016 Results

Q2 2016 Results

Record sales of $22.4mm, +13% vs. Q2 2015
Gross margin of 68.6% vs. 66.0%
Record op. income of $3.8mm vs. $2.8mm, +35%
Op. margin of 17% vs. 14%
Record net income of $2.6mm vs. $1.8mm, +47%
Record earnings of $0.14 per diluted share vs. $0.10, +40%
Record EBITDA of $4.8mm vs. $3.7mm, +30%
Cash & equivalents up $3.4mm to $29.3mm

Q2 2016 sales of $22.4mm increased 13% (+10% organic) vs. Q2 2015. XenoSure and valvulotomes led growth. International sales increased 22%, while The Americas grew 7%.

Read more at https://www.stockhouse.com/news/press-releases/2016/07/27/lemaitre-q2-2016-record-sales-22-4mm-13-record-op-income-3-8mm#OYkBmGj4KWrpLG2W.99

<< Previous

Bullboard Posts

Next >>

Top 3 aerospace and defence stocks to buy on the TSX